Quarterly report pursuant to Section 13 or 15(d)

Commitments and Contingencies (Details Narrative)

v3.20.2
Commitments and Contingencies (Details Narrative) - USD ($)
1 Months Ended 9 Months Ended 12 Months Ended
May 31, 2019
Apr. 30, 2017
Sep. 30, 2020
Dec. 31, 2019
Dec. 31, 2018
Exercise price per share     $ 12.50    
Agrarian Technologies LLC [Member]          
license fee     $ 37,500    
Employment Agreement [Member] | CEO [Member]          
Base salary   $ 350,000      
Employment Agreement [Member] | President and General Counsel [Member]          
Base salary   220,000      
Services Agreement [Member]          
Number of warrants         6,000
Average remaining term in years         5 years
Exercise price per share         $ 1.00
License Agreement [Member]          
license fee $ 30,000   37,500 $ 15,000  
License Agreement [Member] | QSAM Therapeutics Inc [Member]          
license fee     60,000    
Payments for milestone   60,000      
Other expense reimbursements   $ 150,000 60,000    
Equity method investment ownership percentage   5.00%      
Royalty percentage   4.50%      
Total cost,involved in connection with license     120,000    
License Agreement [Member] | QSAM Therapeutics Inc [Member] | Drug Development Costs Paid to Service Providers [Member]          
Total cost,involved in connection with license     $ 86,943    
License Agreement [Member] | QSAM Therapeutics Inc [Member] | Maximum [Member]          
Royalty percentage   50.00%